poster

Poster

Add-on Pimavanserin Improves Insomnia, Sleepiness in MDD Study

09/13/2020

A secondary analysis of a study investigating adjunctive pimavanserin for the treatment of patients with major depressive disorder found that it significantly improved insomnia and sleepiness, researchers reported at Psych Congress 2020.

A secondary analysis of a study...

09/13/2020

Psych Congress Network

Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant Antidepressant: Post Hoc Analysis of Four Short-Term Studies

Background: We aimed to determine the effects of adjunctive brexpiprazole on sexual functioning in adults with major depressive disorder (MDD), according to antidepressant treatment (ADT)...

11/22/2019

Lumateperone in the Treatment of Schizophrenia: Efficacy in Demographic and Clinical Subgroups

Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...

11/22/2019

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

11/22/2019

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

11/22/2019

Relationship Between ADHD Symptom and Executive Function Improvement in Adult ADHD in SHP465 Mixed Amphetamine Salts Extended-Release Clinical Trials

Adult attention-deficit/hyperactivity disorder (ADHD) is associated with impaired executive function (EF). This post hoc analysis examines relationships between changes in ADHD symptoms a...

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

11/22/2019

Post Hoc Responder Analyses of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults With Attention-Deficit/Hyperactivity Disorder

In adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release reduced ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) significantl...

11/22/2019

A Collaborative Study to Assess Digitally Enabled Engagement in Major Depressive Disorder (MDD) Within a Large Health System

Objective: Assessment of a digitally enabled care Pathway mobile app designed to improve patient-provider engagement in patients with MDD. A patient interface was used to assess treatment...

11/22/2019

Association of Depression Severity With Acute Risk of ER Visits and Hospitalizations Among Adults With Major Depressive Disorder

Introduction: Although major depressive disorder (MDD) is the leading cause of disability worldwide, the relationship between depression severity and risk of ER visit/hospitalization is u...

11/22/2019

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products